Search the Newsreel

Brightview Holdings Inc (BV) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Brightview Holdings Inc (BV), noting its current valuation score of 7.92, ranking 118 out of 159 in its industry. The company's P/E ratio is 439.75, which is 11.49% below its recent high and significantly above its recent …

BV Financial Inc (BVFL) Institutional Confidence

BV Financial Inc (BVFL) has an institutional shareholding score of 3.00, placing it 250th out of 395 in the Banking Services industry. The institutional shareholding proportion is 39.77%, which is a 42.46% decrease quarter-over-quarter. Bill Nygren | OAKMX is the largest institutional shareholder, holding …

ATAI Life Sciences NV (ATAI) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for ATAI Life Sciences NV (ATAI), ranking it 99 out of 385 in the Biotechnology & Medical Research industry with a score of 4.10. Key metrics include a beta of 1.60, indicating higher volatility than the S&P 500, …

New Century Logistics (BVI) Ltd (NCEW) Financial Health: Profitability & Balance Sheet Analysis

This article provides a detailed financial analysis of New Century Logistics (BVI) Ltd (NCEW), presenting its profitability and balance sheet data. It includes key financial indicators from the FY2025 earnings report, such as revenue, EPS, various assets and liabilities, and profitability ratios. The analysis …

Banco Bbva Argentina SA (BBAR) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Banco Bbva Argentina SA (BBAR), indicating a current risk score of 3.78 and placing it 350th out of 394 in the Banking Services industry. The company's beta of 1.00 suggests it mirrors the S&P 500's volatility, outperforming …

AbbVie, Inc. CDR (CAD Hedged) Revenue Breakdown – NEO:ABBV

This article provides a revenue breakdown for AbbVie, Inc. CDR (CAD Hedged) under the ticker NEO:ABBV, sourced from TradingView. It highlights that the United States was the primary contributor to AbbVie's revenue, bringing in 65.12 billion CAD last year and 58.95 billion CAD the …

AbbVie, Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.0625 Sh Revenue Breakdown – BMFBOVESPA:ABBV34 – TradingView

This article provides a revenue breakdown for AbbVie, Inc. Brazilian Depository Receipts (ABBV34) traded on the BMFBOVESPA, highlighting that the United States is the largest contributor to its revenue. The financial data indicates significant revenue in BRL during the last two years.

The Real Price of AbbVie Stock Is Cheaper Than You Think

AbbVie (ABBV) stock appears expensive at first glance with a high price-to-earnings multiple, but a deeper analysis reveals it's cheaper than it seems. When factoring in expected earnings by 2027, the stock's valuation drops significantly due to anticipated growth. This "forward discount" is driven …

Aberdeen Group (PRQR) discloses 6.33% ProQR Therapeutics stake via abrdn Inc.

Aberdeen Group plc and its affiliate abrdn Inc. have disclosed a beneficial ownership of 8,932,507 Ordinary Shares in ProQR Therapeutics N.V., representing 6.33% of the class. Both entities report shared voting and dispositive power over these shares, which abrdn Inc. holds on behalf of …

ProQR Therapeutics BV (NASDAQ: PRQR) Share Price, PRQR Stock News, PRQR Share Price & Updates

Forget Weight Loss Drugs: Here's Another Reason to Buy Eli Lilly Stock

Eli Lilly (NYSE: LLY) brought in $19.8 billion in revenue in the first quarter of 2026, and most of it can be traced back to the medicines everyone has heard of by now: tirzepatide, sold as Mounjaro for type 2 diabetes and Zepbound for …

AbbVie (ABBV) Stock May Be Mispriced On Its 172% Run

AbbVie (ABBV) has seen strong returns over five years (172%), but its current valuation presents a mixed picture. While a Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 43.4% at an intrinsic value of $465 per share, its Price-to-Earnings (P/E) ratio …

Eli Lilly Is Acquiring AtaiBeckley for $2.8 Billion. Cathie Wood Thinks Another Psychedelic Drug Stock Is an Even Better Bet.

The psychedelic medicine field looks like it's finally about to take off, and that's catching the attention of portfolio managers like Cathie Wood. Eli Lilly (NYSE: LLY) agreed on July 16 to acquire the biotech AtaiBeckley (NASDAQ: ATAI) for a $2.8 billion upfront payment, …

AbbVie wins EU clearance for Rinvoq as first systemic treatment for non-segmental vitiligo (ABBV:NYSE)

AbbVie announced that the European Commission has approved Rinvoq for the treatment of adult and adolescent patients aged 12 years and older with non-segmental vitiligo, who are candidates for systemic therapy. This approval marks Rinvoq as the first systemic treatment of its kind for …

Banco BBVA Argentina Number of Employees 2026 | Employee Count & Headcount Data

Banco BBVA Argentina (BBAR) has approximately 6,129 employees worldwide as of March 2026, representing an 18.4% growth since 2023. The company is actively hiring, with 32 job postings in 2026, and its workforce is predominantly located in Argentina. The average employee salary is $24,929, …

PRQR|ProQR Therapeutics NV|Price:1.755|Chg%:+0.025

This article provides a comprehensive stock analysis of ProQR Therapeutics NV (PRQR), highlighting its healthy fundamentals, high growth potential, and fair valuation within the Biotechnology & Medical Research industry. It notes strong institutional ownership and a "Buy" rating from analysts with a target price …

AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Non-Segmental Vitiligo

RINVOQ is the first and only systemic medication approved in the European Union to treat adult and adolescent patients with non-segmental vitiligo (NSV) The approval is supported by data from the Phase 3 Viti-Up clinical program, which showed that RINVOQ achieved statistically significant total …

ADAR1 Capital Management LLC Acquires New Shares in DBV Technologies S.A. $DBVT

EU Approves AbbVie's RINVOQ After Trials Show Complete Scalp Hair Regrowth

The European Commission has approved AbbVie's RINVOQ (upadacitinib) for treating severe alopecia areata in adults and adolescents aged 12 and older. This approval is supported by Phase 3 trials where RINVOQ demonstrated significant scalp hair regrowth, including complete regrowth in some patients, at both …

(BVFL) Movement Within Algorithmic Entry Frameworks

This article provides an algorithmic analysis for Bv Financial Inc. (NASDAQ: BVFL), highlighting a near-term strong sentiment influencing a mid-term neutrality towards a long-term positive bias. It details several institutional trading strategies including position, momentum, and risk hedging, alongside a multi-timeframe signal analysis and …

Liquidity Mapping Around (BV) Price Events

This article analyzes Brightview Holdings Inc. (NYSE: BV) using AI models to provide liquidity mapping and trading strategies. Key findings indicate a neutral sentiment, with resistance being tested, and offers specific position, momentum, and risk-hedging strategies for different risk profiles. The analysis highlights an …

AbbVie Announces Availability of ELAHERE® (mirvetuximab soravtansine) in Singapore for the Treatment of Platinum-Resistant Ovarian Cancer

AbbVie has announced the availability of ELAHERE (mirvetuximab soravtansine) in Singapore for treating platinum-resistant ovarian cancer. This antibody-drug conjugate (ADC) is the first and only one approved for patients with FRα-positive high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have undergone …

ABVC BioPharma (ABVC) to vote on 2026 equity plan and Taiwan land-share issuance

ABVC BioPharma is holding a virtual special shareholder meeting on September 18, 2026, to vote on three key proposals. These include approving a new 2026 Equity Incentive Plan, ratifying equity awards granted after February 16, 2026, and authorizing the issuance of up to 6,638,591 …

AbbVie Inc (ABBV) director adds stock-equivalent units after 25.5% 12-week rise

The insider acquisition lands with the biopharma stock still in an active weekly trend, though latest volume ran below its 13-week average.

Botox Maker Tops Buy Point, But Here Comes The Earnings Report

AbbVie closed above the 230.47 buy point from a cup-with-handle base on June 23 and has climbed 15% from there. The previous day, the stock jumped more than 6% after AbbVie announced it agreed to acquire Apogee Therapeutics. The $10.9 billion deal would strengthen …

Should You Buy, Hold or Sell ABBV Stock Ahead of Q2 Earnings?

AbbVie ABBV is set to report second-quarter 2026 earnings on July 31, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter's sales is pinned at $16.81 billion, while earnings per share (EPS) are estimated at $3.66. Both metrics indicate an increase …

ProQR Therapeutics (NASDAQ:PRQR) Director Bart Filius Buys 150,000 Shares

ProQR Therapeutics Director Bart Filius increased his stake in the company by purchasing 150,000 shares for $258,000, doubling his total ownership to 300,000 shares. This follows a similar purchase in June. Shares of ProQR (NASDAQ:PRQR) traded down slightly and the company, valued at $181.75 …

AbbVie Inc. stock outperforms competitors on strong trading day

AbbVie Inc. (ABBV) stock advanced 2.45% to $263.20 on Tuesday, outperforming the S&P 500 Index and the Dow Jones Industrial Average. The company also reached a new 52-week high, exceeding its previous peak from the day before.

AbbVie Inc Stock (ABBV) Moved Up by 3.35% on Jul 28: A Full Analysis

AbbVie Inc (ABBV) saw its stock rise by 3.35% on July 28, outperforming the Pharmaceuticals & Medical Research sector. This strong performance was attributed to robust second-quarter earnings, significant growth in its immunology drugs Skyrizi and Rinvoq, and positive late-stage clinical trial data in …

ATAI Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of AtaiBeckley to Eli Lilly

MONSEY, N.Y., July 28, 2026 (GLOBE NEWSWIRE) -- The Monsey law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of AtaiBeckley, Inc. (Nasdaq: ATAI) (“AtaiBeckley”) to Eli Lilly and Company (“Lilly”), pursuant to which AtaiBeckley shareholders will receive …

Barclays Adjusts AbbVie PT to $300 From $275, Maintains Overweight Rating

Barclays has increased its price target for AbbVie (ABBV) to $300 from $275, while reiterating an Overweight rating on the stock. The adjustment reflects an updated outlook from the analytical firm regarding the pharmaceutical company's future performance. AbbVie specializes in therapeutic drug research and …

Goldman Sachs uncovers key AbbVie stock signals before earnings

BrightView (BV) Projected to Announce Quarterly Earnings on Tuesday

BBVA Banco Frances S.A. (NYSE:BBAR) Given Consensus Rating of "Moderate Buy" by Brokerages

ABVC Biopharma Inc (ABVC) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of ABVC Biopharma Inc's (ABVC) dividend history and stock split events. It indicates that the company has not distributed any dividends in the past five years and lists several merger-related stock splits that occurred on July 24, 2023, each …

ABVC Biopharma Inc (ABVC) Cash Flow

This article provides a detailed cash flow statement for ABVC Biopharma Inc (ABVC), encompassing quarterly and annual data for operating, investing, and financing activities. It also includes frequently asked questions explaining different types of cash flow and their significance for the company's financial health. …